Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer

Cancer statistics, 2013

Siegel, R., Naishadham, D., & Jemal, A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21166 · Cited by 11,825

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P. G., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,895

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848

Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion

Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer

Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170

Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice

Hingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609

Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma

Rhim, A. D., Oberstein, P. E., Thomas, D. H., Mirek, E. T., Palermo, C. F., Sastra, S. A., Dekleva, E. N., Saunders, T., Becerra, C. P., Tattersall, I. W., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.021 · Cited by 2,085

Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis

Thayer, S. P., di Magliano, M. P., Heiser, P. W., Nielsen, C. M., Roberts, D. J., Lauwers, G. Y., Qi, Y., Gysin, S., Castillo, C. F. F.-D., Yajnik, V., et al. (2003) · Nature · doi:10.1038/nature02009 · Cited by 1,479

SHH pathway inhibition is protumourigenic in adamantinomatous craniopharyngioma

Carreno, G., Boult, J. K. R., Apps, J. R., González-Meljem, J. M., Haston, S., Guiho, R., Stache, C., Danielson, L. S., Koers, A., Smith, L. M., et al. (2019) · Endocrine Related Cancer · doi:10.1530/erc-18-0538 · Cited by 40

Stroma-targeting strategies in pancreatic cancer: Past lessons, challenges and prospects

Polani, F., Grierson, P. M., & Lim, K. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i18.2105 · Cited by 42

Canonical Hedgehog Pathway and Noncanonical GLI Transcription Factor Activation in Cancer

Suchors, C., & Kim, J. (2022) · Cells · doi:10.3390/cells11162523 · Cited by 45

Latest Advances in the Use of Therapeutic Focused Ultrasound in the Treatment of Pancreatic Cancer

Mouratidis, P., & ter Haar, G. (2022) · Cancers · doi:10.3390/cancers14030638 · Cited by 40

Enhancing the Efficacy of CAR T Cells in the Tumor Microenvironment of Pancreatic Cancer

Henze, J., Tacke, F., Hardt, O., Alves, F., & Rawashdeh, W. A. (2020) · Cancers · doi:10.3390/cancers12061389 · Cited by 39

Hedgehog Signaling in Colorectal Cancer: All in the Stroma?

Geyer, N., & Gerling, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031025 · Cited by 40

Therapeutic advances in metastatic pancreatic cancer: a focus on targeted therapies

Turpin, A., Neuzillet, C., Colle, E., Dusetti, N., Nicolle, R., Cros, J. F., de Mestier, L., Bachet, J., & Hammel, P. R. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221118019 · Cited by 41

Cancer-Associated Fibroblasts: Lessons from Pancreatic Cancer

Sherman, M. H., & di Magliano, M. P. (2023) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061421-035400 · Cited by 39

Do anti-stroma therapies improve extrinsic resistance to increase the efficacy of gemcitabine in pancreatic cancer?

Liang, C., Shi, S., Meng, Q., Liang, D., Ji, S., Zhang, B., Qin, Y., Xu, J., Ni, Q., & Yu, X. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2678-7 · Cited by 39

Fibroblast-derived prolargin is a tumor suppressor in hepatocellular carcinoma

Chiavarina, B., Ronca, R., Otaka, Y., Sutton, R. B., Rezzola, S., Yokobori, T., Chiodelli, P., Souche, F.-R., Pourquier, D., Maraver, A., et al. (2022) · Oncogene · doi:10.1038/s41388-021-02171-z · Cited by 39

Recent advances in targeted therapy for pancreatic adenocarcinoma

Fang, Y., Yang, W., Niu, Y., & Sun, Y. (2023) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v15.i4.571 · Cited by 40

Current Standard and Future Perspectives in First- and Second-Line Treatment of Metastatic Pancreatic Adenocarcinoma

Ellenrieder, V., König, A. O., & Seufferlein, T. T. W. (2016) · Digestion · doi:10.1159/000447739 · Cited by 38

PDE3 inhibitor and EGCG combination treatment suppress cancer stem cell properties in pancreatic ductal adenocarcinoma

Kumazoe, M., Takai, M., Hiroi, S., Takeuchi, C., Yamanouchi, M., Nojiri, T., Onda, H., Bae, J., Huang, Y., Takamatsu, K., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-02162-9 · Cited by 38

GDC-0449 improves the antitumor activity of nano-doxorubicin in pancreatic cancer in a fibroblast-enriched microenvironment

Zhou, Q., Zhou, Y., Liu, X., & Shen, Y. (2017) · Scientific Reports · doi:10.1038/s41598-017-13869-0 · Cited by 38

Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions

Zhang, Y., Yang, C., Cheng, H., Fan, Z., Huang, Q., Yu, L., Fan, K., Luo, G., Jin, K., Wang, Z., et al. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0551-7 · Cited by 41

Metastatic pancreatic cancer: Mechanisms and detection (Review)

Chen, X., Liu, F., Xue, Q., Weng, X., & Xu, F. (2021) · Oncology Reports · doi:10.3892/or.2021.8182 · Cited by 38

Dynamic Stromal Alterations Influence Tumor-Stroma Crosstalk to Promote Pancreatic Cancer and Treatment Resistance

Murphy, K. J., Chambers, C. R., Herrmann, D., Timpson, P., & Pereira, B. (2021) · Cancers · doi:10.3390/cancers13143481 · Cited by 37

Therapeutic Strategies to Overcome Fibrotic Barriers to Nanomedicine in the Pancreatic Tumor Microenvironment

Tanaka, H. Y., Nakazawa, T., Enomoto, A., Masamune, A., & Kano, M. R. (2023) · Cancers · doi:10.3390/cancers15030724 · Cited by 42

SiATG5-loaded cancer cell membrane-fused liposomes induced increased uptake of albumin-bound chemotherapeutics by pancreatic cancer cells

Yan, J., Wang, M., Lv, S., Chen, D., Wu, Z., Zhou, D., Zhang, S., Lv, J., Xu, K., Xu, C., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.01.055 · Cited by 37

Dynamic Contrast-enhanced MRI Detects Responses to Stroma-directed Therapy in Mouse Models of Pancreatic Ductal Adenocarcinoma

Cao, J., Pickup, S., Clendenin, C. J., Blouw, B., Choi, H., Kang, D. W., Rosen, M. A., O'Dwyer, P. J., & Zhou, R. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2276 · Cited by 37

ATM Regulates Differentiation of Myofibroblastic Cancer-Associated Fibroblasts and Can Be Targeted to Overcome Immunotherapy Resistance

Mellone, M., Piotrowska, K., Venturi, G., James, L., Bzura, A., Lopez, M. A., James, S., Wang, C., Ellis, M. J., Hanley, C. J., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0435 · Cited by 36

EVI1 modulates oncogenic role of GPC1 in pancreatic carcinogenesis

Tanaka, M. H., Ishikawa, S., Ushiku, T., Morikawa, T., Isagawa, T., Yamagishi, M., Yamamoto, H., Katoh, H., Takeshita, K., Arita, J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20601 · Cited by 36

Introduction of WT-TP53 into pancreatic cancer cells alters sensitivity to chemotherapeutic drugs, targeted therapeutics and nutraceuticals

Abrams, S. L., Lertpiriyapong, K., Yang, L. V., Martelli, A. M., Cocco, L., Ratti, S., Falasca, M., Murata, R. M., Rosalen, P. L., Lombardi, P., et al. (2018) · Advances in Biological Regulation · doi:10.1016/j.jbior.2018.06.002 · Cited by 36

Nanomedicine for Imaging and Therapy of Pancreatic Adenocarcinoma

Brachi, G., Bussolino, F., Ciardelli, G., & Mattu, C. (2019) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2019.00307 · Cited by 36

Targeting hedgehog signaling in pancreatic ductal adenocarcinoma

Quatannens, D., Verhoeven, Y., van Dam, P. A., Lardon, F., Prenen, H., Roeyen, G., Peeters, M., Smits, E., & Audenaerde, J. R. M. V. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108107 · Cited by 37

Combinatorial Gli activity directs immune infiltration and tumor growth in pancreatic cancer

Scales, M. K., Velez-Delgado, A., Steele, N. G., Schrader, H. E., Stabnick, A. M., Yan, W., Mercado-Soto, N. M., Nwosu, Z., Johnson, C. N., Zhang, Y.-Q., et al. (2022) · PLoS Genetics · doi:10.1371/journal.pgen.1010315 · Cited by 28

Transcriptome Landscape of Cancer‐Associated Fibroblasts in Human PDAC

Tao, M., Liu, W., Chen, J., Liu, R., Zou, J., Yu, B., Wang, C., Huang, M., Chen, Q., Zhang, Z., et al. (2025) · Advanced Science · doi:10.1002/advs.202415196 · Cited by 50

Hepatotoxicity with Vismodegib: An MD Anderson Cancer Center and Research on Adverse Drug Events and Reports Project

Edwards, B. J.-A., Raisch, D. W., Saraykar, S., Sun, M., Hammel, J. A., Tran, H. T., Wehr, N. H., Arabyat, R. M., & West, D. P. (2017) · Drugs in R&D · doi:10.1007/s40268-016-0168-2 · Cited by 35

Therapeutic Targeting Strategies of Cancer Stem Cells in Gastrointestinal Malignancies

Sonbol, M. B., Ahn, D. H., & Bekaii‐Saab, T. (2019) · Biomedicines · doi:10.3390/biomedicines7010017 · Cited by 35

Understanding Abnormal SMO-SHH Signaling in Autism Spectrum Disorder: Potential Drug Target and Therapeutic Goals

Rahi, S., & Mehan, S. (2020) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-020-01010-1 · Cited by 38

Moving the Needle on Precision Medicine in Pancreatic Cancer

O'Kane, G. M., & Lowery, M. A. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02514 · Cited by 34

Cancer-Associated Fibroblasts in Pancreatic Cancer: Should They Be Deleted or Reeducated?

Qu, C., Wang, Q., Meng, Z., & Wang, P. (2018) · Integrative Cancer Therapies · doi:10.1177/1534735418794884 · Cited by 34

Clinical Strategies Targeting the Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma

Skorupan, N., Domínguez, M. P., Ricci, S. L., & Alewine, C. (2022) · Cancers · doi:10.3390/cancers14174209 · Cited by 35

What treatment in 2017 for inoperable pancreatic cancers?

Taı̈eb, J., Pointet, A., Laethem, J. V., Laquente, B., Pernot, S., Lordick, F., & Reni, M. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx174 · Cited by 33

Tumor Priming by SMO Inhibition Enhances Antibody Delivery and Efficacy in a Pancreatic Ductal Adenocarcinoma Model

Wang, J., Chan, D. K. W., Sen, A., Ma, W. W., & Straubinger, R. M. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0354 · Cited by 32

From Genetic Alterations to Tumor Microenvironment: The Ariadne’s String in Pancreatic Cancer

Bazzichetto, C., Conciatori, F., Luchini, C., Simionato, F., Santoro, R., Vaccaro, V., Corbo, V., Falcone, I., Ferretti, G., Cognetti, F., et al. (2020) · Cells · doi:10.3390/cells9020309 · Cited by 32

Modulation of Cancer-Associated Fibrotic Stroma by An Integrin αvβ3 Targeting Protein for Pancreatic Cancer Treatment

Turaga, R. C., Sharma, M., Mishra, F., Krasinskas, A. M., Yuan, Y., Yang, J. J., Wang, S., Liu, C., Li, S., & Liu, Z. (2020) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2020.08.004 · Cited by 33

Pharmacologic Normalization of Pancreatic Cancer-Associated Fibroblast Secretome Impairs Prometastatic Cross-Talk With Macrophages

Samain, R., Brunel, A., Douché, T., Fanjul, M., Cassant‐Sourdy, S., Rochotte, J., Cros, J. F., Neuzillet, C., Raffenne, J., Duluc, C., et al. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.01.008 · Cited by 32

Nab-Paclitaxel in the Treatment of Gastrointestinal Cancers—Improvements in Clinical Efficacy and Safety

Hassan, S., Awasthi, N., Ponna, S., & von Holzen, U. W. (2023) · Biomedicines · doi:10.3390/biomedicines11072000 · Cited by 31

Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors

Stathis, A., Hess, D., von Moos, R., Homicskó, K., Griguolo, G., Joerger, M., Mark, M. T., Ackermann, C. J., Allegrini, S., Catapano, C. V., et al. (2017) · Investigational New Drugs · doi:10.1007/s10637-017-0454-z · Cited by 32

Cancer associated fibroblasts tailored tumor microenvironment of therapy resistance in gastrointestinal cancers

Sun, Y., Wang, R., Qiao, M., Yan-chun, X., Guan, W., & Wang, L. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26433 · Cited by 32

Stress responses in stromal cells and tumor homeostasis

Vitale, I., Manic, G., Galassi, C., & Galluzzi, L. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.04.004 · Cited by 33

Desmoplasia and Biophysics in Pancreatic Ductal Adenocarcinoma

Maggio, F. D., & El-Shakankery, K. H. (2020) · Pancreas · doi:10.1097/mpa.0000000000001504 · Cited by 33

A CD10‐OGP Membrane Peptolytic Signaling Axis in Fibroblasts Regulates Lipid Metabolism of Cancer Stem Cells via SCD1

Yu, S., Lu, Y., Su, A., Chen, J., Li, J., Zhou, B., Liu, X., Xia, Q., Li, Y., Li, J., et al. (2021) · Advanced Science · doi:10.1002/advs.202101848 · Cited by 32

Identification, Culture and Targeting of Cancer Stem Cells

Herreros‐Pomares, A. (2022) · Life · doi:10.3390/life12020184 · Cited by 34

Ligand-dependent Hedgehog pathway activation in Rhabdomyosarcoma: the oncogenic role of the ligands

Almazán-Moga, A., Zarzosa, P., Molist, C., Velasco, P., Pyczek, J., Simon‐Keller, K., Giralt, I., Vidal, I., Navarro, N., Segura, M. F., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.305 · Cited by 32

Overcoming the Fibrotic Fortress in Pancreatic Ductal Adenocarcinoma: Challenges and Opportunities

Min, K. K. M., Ffrench, C. B., Jessup, C. F., Shepherdson, M., Barreto, S. G., & Bonder, C. S. (2023) · Cancers · doi:10.3390/cancers15082354 · Cited by 35

Novel agents for advanced pancreatic cancer

Akinleye, A., Iragavarapu, C., Furqan, M., Cang, S., & Liu, D. (2015) · Oncotarget · doi:10.18632/oncotarget.3999 · Cited by 31

The inhibition of heme oxygenase-1 enhances the chemosensitivity and suppresses the proliferation of pancreatic cancer cells through the SHH signaling pathway

Han, L., Jiang, J., Ma, Q., Wu, Z., & Wang, Z. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4363 · Cited by 31

Shattering the castle walls: Anti-stromal therapy for pancreatic cancer

Kanat, Ö., & Ertaş, H. (2018) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v10.i8.202 · Cited by 31

Cancer-associated fibroblasts in therapeutic resistance of pancreatic cancer: Present situation, predicaments, and perspectives

Han, X., Zhang, W.-H., Wang, W., Yu, X., & Liu, L. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188444 · Cited by 31

Pancreatic cancer stem cells may define tumor stroma characteristics and recurrence patterns in pancreatic ductal adenocarcinoma

Askan, G., Şahin, İ. H., Chou, J. F., Yavas, A., Capanu, M., Iacobuzio–Donahue, C. A., Baştürk, O., & O'Reilly, E. M. (2021) · BMC Cancer · doi:10.1186/s12885-021-08123-w · Cited by 31

Reproducibility of academic preclinical translational research: lessons from the development of Hedgehog pathway inhibitors to treat cancer

Curran, T. (2018) · Open Biology · doi:10.1098/rsob.180098 · Cited by 30

Fibroblast Reprogramming in Gastrointestinal Cancer

Melissari, M., Chalkidi, N., Sarris, M. E., & Koliaraki, V. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00630 · Cited by 30

Clinical and Pre-Clinical Evidence of Carbonic Anhydrase IX in Pancreatic Cancer and Its High Expression in Pre-Cancerous Lesions

Strapcova, S., Takáčová, M., Csáderová, L., Martinelli, P., Lukáčiková, Ľ., Gál, V., Kopáček, J., & Švastová, E. (2020) · Cancers · doi:10.3390/cancers12082005 · Cited by 30

Nanoparticle combination for precise stroma modulation and improved delivery for pancreatic cancer

Tarannum, M., Holtzman, K., Dréau, D., Mukherjee, P., & Vivero-Escoto, J. L. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.05.019 · Cited by 30

Inhibiting Hedgehog: An Update on Pharmacological Compounds and Targeting Strategies

Galperin, I., Dempwolff, L., Diederich, W. E., & Lauth, M. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00188 · Cited by 29

GPCRs in pancreatic adenocarcinoma: Contributors to tumour biology and novel therapeutic targets

Sriram, K., Salmerón, C., Wiley, S. Z., & Insel, P. A. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15028 · Cited by 29

Molecular Therapeutics of Pancreatic Ductal Adenocarcinoma: Targeted Pathways and the Role of Cancer Stem Cells

Stoica, A.-F., Chang, C., & Pauklin, S. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.09.008 · Cited by 30

Advances in Targeted Therapy and Immunotherapy for Pancreatic Cancer

Liu, X., Li, Z., & Wang, Y. (2021) · Advanced Biology · doi:10.1002/adbi.201900236 · Cited by 29

Implications of the microbiome in the development and treatment of pancreatic cancer: Thinking outside of the box by looking inside the gut

Yu, Q., Jobin, C., & Thomas, R. M. (2021) · Neoplasia · doi:10.1016/j.neo.2020.12.008 · Cited by 31

Targeting Tumour-Associated Fibroblasts in Cancers

Shah, K., Mallik, S. B., Gupta, P. K., & Iyer, A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.908156 · Cited by 31

Imatinib facilitates gemcitabine sensitivity by targeting epigenetically activated PDGFC signaling in pancreatic cancer

Shi, Y.-H., Xu, Q., Zhu, Y., Liu, Z., Zhao, G., Liu, Q., Wang, X.-Y., Wang, J., Xu, X. S., Su, Q., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.11.004 · Cited by 29

HPV+ve/−ve oral-tongue cancer stem cells: A potential target for relapse-free therapy

Gupta, S., Kumar, P., & Das, B. C. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100919 · Cited by 29

Molecular and Phenotypic Profiling for Precision Medicine in Pancreatic Cancer: Current Advances and Future Perspectives

Miyabayashi, K., Nakagawa, H., & Koike, K. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.682872 · Cited by 28

Modulation of the antitumor immune response by cancer-associated fibroblasts: mechanisms and targeting strategies to hamper their immunosuppressive functions

Thiery, J. (2022) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2022.00103 · Cited by 29

Micelle Mixtures for Coadministration of Gemcitabine and GDC-0449 To Treat Pancreatic Cancer

Karaca, M., Dutta, R., Özsoy, Y., & Mahato, R. I. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00971 · Cited by 28

Emerging from their burrow: Hedgehog pathway inhibitors for cancer

Gan, G. N., & Jimeno, A. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1216973 · Cited by 28

Hedgehog signaling regulates PDL-1 expression in cancer cells to induce anti-tumor activity by activated lymphocytes

Onishi, H., Fujimura, A., Oyama, Y., Yamasaki, A., Imaizumi, A., Kawamoto, M., Katano, M., Umebayashi, M., & Morisaki, T. (2016) · Cellular Immunology · doi:10.1016/j.cellimm.2016.08.003 · Cited by 28

Pharmacotherapeutic strategies for treating pancreatic cancer: advances and challenges

Diab, M., Azmi, A. S., Mohammad, R. M., & Philip, P. A. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1561869 · Cited by 28

Targeted Therapy for Highly Desmoplastic and Immunosuppressive Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma

Olaoba, O. T., Yang, M. J., Adelusi, T. I., Maidens, T., Kimchi, E. T., Staveley-O’Carroll, K. F., & Li, G. (2024) · Cancers · doi:10.3390/cancers16081470 · Cited by 28

Pancreatic cancer from bench to bedside: molecular pathways and treatment options

Kosmidis, C. S., Sapalidis, K. G., Kotidis, E. V., Mixalopoulos, N., Zarogoulidis, P., Tsavlis, D., Baka, S., Man, Y.-G., & Kanellos, J. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.05.11 · Cited by 26

Deciphering the Role of Innate Immune NF-ĸB Pathway in Pancreatic Cancer

Khurana, N., Dodhiawala, P. B., Bulle, A. S., & Lim, K. (2020) · Cancers · doi:10.3390/cancers12092675 · Cited by 27

Defining the Role of GLI/Hedgehog Signaling in Chemoresistance: Implications in Therapeutic Approaches

Chai, J. Y., Sugumar, V., Al-Shanon, A. F., Wong, W. F., Fung, S. Y., & Looi, C. Y. (2021) · Cancers · doi:10.3390/cancers13194746 · Cited by 30

Small molecule tyrosine kinase inhibitors and pancreatic cancer—Trials and troubles

Bhaskar, L. V., Farran, B., Lakkakula, S., Peela, S., Yarla, N. S., Bramhachari, P. V., Kamal, M. A., Saddala, M. S., & Nagaraju, G. P. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.09.011 · Cited by 26

Immunological combination treatment holds the key to improving survival in pancreatic cancer

Sodergren, M. H., Mangal, N., Wasan, H. S., Sadanandam, A., Balachandran, V. P., Jiao, L. R., & Habib, N. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03332-5 · Cited by 25

Tumor and stroma COL8A1 secretion induces autocrine and paracrine progression signaling in pancreatic ductal adenocarcinoma

Yan, B., Liu, L., Zhao, L., Hinz, U., Luo, Y., An, X., Gladkich, J., Torre, C. D. L., Huang, Z., Schrapel, D., et al. (2022) · Matrix Biology · doi:10.1016/j.matbio.2022.11.002 · Cited by 26

Precision treatment of pancreatic ductal adenocarcinoma

Wei, H., & Ren, H. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216636 · Cited by 25

Metastatic heterogeneity in pancreatic cancer: mechanisms and opportunities for targeted intervention

Maddipati, R. (2025) · Journal of Clinical Investigation · doi:10.1172/jci191943 · Cited by 31

Insights into the relevance of targeting fibroblasts to control cancer

Boeker, V., & Kalluri, R. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102395 · Cited by 25

Stromal Protein-Mediated Immune Regulation in Digestive Cancers

Gamradt, P., de la Fouchardière, C., & Hennino, A. (2021) · Cancers · doi:10.3390/cancers13010146 · Cited by 27

Nuclear receptor coactivator SRC-1 promotes colorectal cancer progression through enhancing GLI2-mediated Hedgehog signaling

Guo, P., Chen, Q., Peng, K., Xie, J., Liu, J., Ren, W., Tong, Z., Li, M., Xu, J., Zhang, Y., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02308-8 · Cited by 25

Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomas

Neuzillet, C., Rousseau, B., Kocher, H. M., Bourget, P., & Tournigand, C. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.028 · Cited by 25

How does the tumor microenvironment play a role in hepatobiliary tumors?

Kamil, F., & Rowe, J. H. (2018) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2017.06.09 · Cited by 25

Reviewing the Utility of EUS FNA to Advance Precision Medicine in Pancreatic Cancer

Berry, W., Lundy, J., Croagh, D. G., & Jenkins, B. J. (2018) · Cancers · doi:10.3390/cancers10020035 · Cited by 27

Stroma — A Double-Edged Sword in Pancreatic Cancer

Gu, J., Saiyin, H., Fu, D., & Li, J. (2018) · Pancreas · doi:10.1097/mpa.0000000000001023 · Cited by 24

Molecular ZIP codes in targeted drug delivery

Ruoslahti, E. I. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2200183119 · Cited by 28

Mechanoregulation of Metastasis beyond the Matrix

Er, E. E., Tello‐Lafoz, M., & Huse, M. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0419 · Cited by 22

Pancreatic ductal adenocarcinoma: tumor microenvironment and problems in the development of novel therapeutic strategies

Kuznetsova, A. V., Попова, О. П., Panchenkov, D. N., Dyuzheva, Т. G., & Aa, I. (2022) · Clinical and Experimental Medicine · doi:10.1007/s10238-022-00886-1 · Cited by 24

KRAS as a Key Oncogene in the Clinical Precision Diagnosis and Treatment of Pancreatic Cancer

Dai, M., Chen, S., Teng, X., Chen, K., & Cheng, W. (2022) · Journal of Cancer · doi:10.7150/jca.76695 · Cited by 28

Increasing cancer permeability by photodynamic priming: from microenvironment to mechanotransduction signaling

Gutierrez, N. M. C., Pujol‐Solé, N., Arifi, Q., Coll, J., Clainche, T. L., & Broekgaarden, M. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10064-0 · Cited by 25

Systemic Therapy for Patients With Pancreatic Cancer: Current Approaches and Opportunities for Novel Avenues Toward Precision Medicine

Ayasun, R., Saridogan, T., Gaber, O., & Şahin, İ. H. (2022) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2022.11.001 · Cited by 22

Reflections on depletion of tumor stroma in pancreatic cancer

Wang, W.-Q., Liu, L., Xu, J.-Z., & Yu, X. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.01.007 · Cited by 24

Medical management of pancreatic cancer: from personalization to broadening treatment strategies

Dusetti, N., Bachet, J., Chanez, B., Neuzillet, C., de Mestier, L., Williet, N., Frauhoffer, N., Nicolle, R., Boilève, A., Turpin, A., et al. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102973 · Cited by 28

Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer

McCleary‐Wheeler, A. L., Carr, R. M., Palmer, S. R., Smyrk, T. C., Allred, J. B., Almada, L. L., Tolosa, E. J., Lamberti, M. J., Marks, D. L., Borad, M. J., et al. (2019) · Pancreatology · doi:10.1016/j.pan.2019.11.011 · Cited by 23

Selecting the optimal parameters for sonoporation of pancreatic cancer in a pre-clinical model

Schultz, C. W., Ponce, G. R. D. G., Langer, A., Liu, J., Dhir, T., Leitch, C., Wessner, C. E., Safont, M. M., Zhang, B., Popa, M. L., et al. (2021) · Cancer Biology & Therapy · doi:10.1080/15384047.2021.1881026 · Cited by 23

Recent Advances in Pancreatic Cancer: Novel Prognostic Biomarkers and Targeted Therapy—A Review of the Literature

Schlick, K., Kiem, D., & Greil, R. (2021) · Biomolecules · doi:10.3390/biom11101469 · Cited by 24

Targeting ROCK2 improves macromolecular permeability in a 3D fibrotic pancreatic cancer microenvironment model

Tanaka, H. Y., Nakazawa, T., Miyazaki, T., Cabral, H., Masamune, A., & Kano, M. R. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.03.041 · Cited by 25

Recent Advances and Prospects for Multimodality Therapy in Pancreatic Cancer

Chadha, A. S., Khoo, A., Aliru, M. L., Arora, H. K., Gunther, J. R., & Krishnan, S. (2016) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2016.05.002 · Cited by 23

Targeting inflammation in pancreatic cancer: Clinical translation

Steele, C. W., Gill, N. A. K., Jamieson, N. B., & Carter, C. R. (2016) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v8.i4.380 · Cited by 23

Final analysis of a phase IB/randomized phase II study of gemcitabine (G) plus placebo (P) or vismodegib (V), a hedgehog (Hh) pathway inhibitor, in patients (pts) with metastatic pancreatic cancer (PC): A University of Chicago phase II consortium study.

Catenacci, D. V. T., Bahary, N., Nattam, S. R., Marsh, R., Wallace, J. A., Rajdev, L. N., Cohen, D. J., Sleckman, B. G., Lenz, H., Stiff, P. J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.4012 · Cited by 39

A phase IB/randomized phase II study of gemcitabine (G) plus placebo (P) or vismodegib (V), a hedgehog (Hh) pathway inhibitor, in patients (pts) with metastatic pancreatic cancer (PC): Interim analysis of a University of Chicago phase II consortium study.

Catenacci, D. V. T., Bahary, N., Edelman, M. J., Nattam, S. R., Marsh, R., Kaubisch, A., Wallace, J. A., Cohen, D. J., Stiff, P. J., Sleckman, B. G., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.4022 · Cited by 20

Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma

Jesus‐Acosta, A. D., Sugar, E. A., O'Dwyer, P. J., Ramanathan, R. K., Hoff, D. D. V., Rasheed, Z. A., Zheng, L., Begum, A., Anders, R. A., Maitra, A., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0683-3 · Cited by 178

Hedgehog-Inhibitor Combo Active in Advanced Pancreatic Cancer

Tuma, R. S. (2012) · Oncology Times · doi:10.1097/01.cot.0000418364.63841.c8

A phase II study of vismodegib, a hedgehog (Hh) pathway inhibitor, combined with gemcitabine and nab-paclitaxel (nab-P) in patients (pts) with untreated metastatic pancreatic ductal adenocarcinoma (PDA).

Jesus‐Acosta, A. D., O'Dwyer, P. J., Ramanathan, R. K., Hoff, D. D. V., Maitra, A., Rasheed, Z. A., Zheng, L., Rajeshkumar, N. V., Le, D. T., Hoering, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.3_suppl.257 · Cited by 53